FDA Panel Says Columbia Labs' (CBRX) Data on Preterm Birth Gel Isn't Sufficient (WPI)
FDA panel votes 13-4 data on Columbia Labs' (Nasdaq: CBRX) is not sufficent on preterm birth gel.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta Therapeutics (SRPT) Pushes Higher Following Positive Article on Approval
- Aduro Biotech (ADRO) Announces Publication of Positive Preclinical Data on BCMA, APRIL in Multiple Myeloma
- SkyWest (SKYW) Tops Q1 Expectations on Top and Bottom Line
Create E-mail Alert Related CategoriesFDA, Hot FDA News, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!